Triple
T6311253
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Novartis |
E141505
|
entity |
| Predicate | notableDrug |
P7501
|
FINISHED |
| Object |
Gleevec
Gleevec is a groundbreaking targeted cancer therapy, best known for treating chronic myeloid leukemia by inhibiting the BCR-ABL tyrosine kinase.
|
E584150
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Gleevec | Statement: [Novartis, notableDrug, Gleevec]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Gleevec Context triple: [Novartis, notableDrug, Gleevec]
-
A.
Brilinta
Brilinta is a prescription antiplatelet medication (ticagrelor) used to reduce the risk of heart attack, stroke, and cardiovascular death in patients with acute coronary syndrome or a history of myocardial infarction.
-
B.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
C.
Xeloda
Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
-
D.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
E.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Gleevec Triple: [Novartis, notableDrug, Gleevec]
Generated description
Gleevec is a groundbreaking targeted cancer therapy, best known for treating chronic myeloid leukemia by inhibiting the BCR-ABL tyrosine kinase.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Gleevec Target entity description: Gleevec is a groundbreaking targeted cancer therapy, best known for treating chronic myeloid leukemia by inhibiting the BCR-ABL tyrosine kinase.
-
A.
Brilinta
Brilinta is a prescription antiplatelet medication (ticagrelor) used to reduce the risk of heart attack, stroke, and cardiovascular death in patients with acute coronary syndrome or a history of myocardial infarction.
-
B.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
C.
Xeloda
Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
-
D.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
E.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c008d00efc8190a36c05b4b4a3bf4b |
completed | March 22, 2026, 3:20 p.m. |
| NER | Named-entity recognition | batch_69c0649d1e048190a3fc7fbce9d2ee57 |
completed | March 22, 2026, 9:52 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c5e461e2ec8190af7198a03edb1ff7 |
completed | March 27, 2026, 1:58 a.m. |
| NEDg | Description generation | batch_69c5e66e8b3c8190bd4cd960b91de473 |
completed | March 27, 2026, 2:07 a.m. |
| NED2 | Entity disambiguation (via description) | batch_69c5e6e40c588190898ad952b71e5b11 |
completed | March 27, 2026, 2:09 a.m. |
Created at: March 22, 2026, 4:28 p.m.